From: (b) (6)
Sent: Fri, 28 Feb 2020 16:54:13 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Urgent Email/Strategy to attack 2019-nCoV coronavirus
Attachments: Nucleotide_Analogues_as_Inhibitors of SARS-CoV Polymerase_2_28_2020.pdf, ATT00001.htm, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.pdf, ATT00002.htm

Pls handle

Sent from my iPhone

Begin forwarded message:

From: Jingyue Ju (b) (6)>
Date: February 28, 2020 at 4:46:04 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Cc: "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6), "directorsincoming@cdc.gov" <directorsincoming@cdc.gov>, "Redfield, Robert R. (CDC/OD)" (b) (6), "Davis, Mindy (NIH/NIAID) [E]" (b) (6)>, "Eakin, Ann (NIH/NIAID) [E]" <(b) (6)>, "Stemmy, Erik (NIH/NIAID) [E]" (b) (6)>, "Sciotti, Rick (NIH/NIAID) [E]" (b) (6) "Schiltz, Helen (NIH/NIAID) [E]" (b) (6)>, "Krafft, Amy (NIH/NIAID) [E]" (b) (6)>
Subject: Re: Urgent Email/Strategy to attack 2019-nCoV coronavirus

Dear Dr. Fauci,

Following my previous email regarding our work on developing strategies to attack the 2019-nCoV coronavirus, I am attaching in this email our experimental results demonstrating that 2 nucleotide analogues are inhibitors of the SARS-CoV polymerase. Since the SARS-CoV polymerase has over 96% similarity to the polymerase from SARS-CoV-2, we expect that the nucleotide analogues, 2'-F,Me-UTP and 3'-F-dTTP, will also inhibit the SARS-CoV-2 polymerase.

At this point, it is imperative that the prodrug forms (one is Sofosbuvir that is FDA approved for HepC) of these molecules begin immediate in vitro testing with infected cells (similar to the studies carried out for Remdesivir and chloroquine in the Cell Research article at the link, https://www.nature.com/articles/s41422-020-0282-0; PDF file of the article also attached) followed by animal testing trials ASAP. Since we do not have access to the SARS-CoV-2 viral strains, we need your assistance to identify resources at the NIH laboratories to embark on this next step